Lipocine Q2 net loss $2.6M; Phase 3 PPD trial misses primary endpoint

Lipocine Inc.

2026-Q2 EPS reported -$0.84 revenue$309,496

Net loss of $2.6M ($0.32 per share) vs $2.2M loss ($0.41 per share) in Q2 2025.
Cash and investments $23.3M at June 30, 2026, up from $14.9M at Dec 31, 2025.
Phase 3 trial of LPCN 1154 for PPD missed primary endpoint; post hoc analysis suggests efficacy; FDA meeting Q3 2026.
TLANDO royalty revenue $190k in Q2 2026, up from $123k; UAE approval for TESTYRA (TLANDO) received July 8, 2026.
New placebo-controlled trial for LPCN 1154 initiated to complement existing data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.